Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220514 · ClinicalTrials.gov registry record
Long-term Effects of COVID-19
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 71
- Enrollment target
NCT05220514: Completed study, sponsored by Mayo Clinic.
NCT05220514 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05220514 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to measure, monitor, and analyze long term effects of SARS-CoV-2. The main purpose is to assess the post-hospitalization outcomes of patients who were diagnosed with SAR-CoV-2 by comparing to patients who were hospitalized with an acute neurological disease.
Interventions
- DRUG (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
- DRUG 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2024-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05220514
The ClinicalTrials.gov registry entry for NCT05220514 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195) is the first listed.
NCT05220514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05220514 about?
NCT05220514 is a clinical study titled "Long-term Effects of COVID-19". The purpose of this study is to measure, monitor, and analyze long term effects of SARS-CoV-2. The main purpose is to assess the post-hospitalization outcomes of patients who were diagnosed with SAR-CoV-2 by comparing to patients who were hospitalized with an acute neurological disease.
What is the current status of trial NCT05220514?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2022-01-19. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT05220514?
The interventions under investigation include: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195) (DRUG), 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB) (DRUG).
Who is sponsoring clinical trial NCT05220514?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.